About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Experimental Medication Shows Promise in Tackling Eczema

by Dr. Enozia Vakil on July 10, 2014 at 9:03 PM
Font : A-A+

 New Experimental Medication Shows Promise in Tackling Eczema

A new study has found that a new medication may be potent enough to treat the most common skin disorder, which is also known as eczema. The findings could eventually bring significant relief for many who suffer intense itching and other troubling features of atopic dermatitis, according to the study's lead author Lisa A. Beck, M.D., professor of Dermatology and Medicine at the University of Rochester Medical Center.

The drug, dupilumab, blocks the action of two proteins involved in inflammation, interleukin-4 and interleukin-13, which play a key role in atopic dermatitis (AD). AD is a common skin disease with troubling signs that include severely dry skin, red lesions that may crust or ooze, skin thickening, and symptoms of intense itching that may lead to skin wounds, infections and sleep disturbance.

Advertisement

Moderate-to-severe AD is a more chronic version of the disease that typically has more systemic features and is seen in up to 3 percent of adults with the disease. AD can impact a person's ability to lead a full and active life. In addition, people with AD are more likely to have asthma and other allergic disorders such as hay fever. Current treatments for AD include topical and oral steroids as well as phototherapy, but their effectiveness is limited or the side effects associated with their chronic use are significant.

"We are encouraged by the consistent findings across these studies, which show that patients treated with dupilumab had a marked improvement in disease activity and itch," Beck said. "At this point, dupilumab appears to be remarkably effective for adults with severe AD, although larger studies are needed to confirm its safety and efficacy."
Advertisement

Dupilumab is administered as a skin injection, and has shown promise in both Phase I and Phase II studies. Participants in a 12-week Phase II study showed a 74 percent reduction in the Eczema Area Severity Index, a tool used to measure the severity of a patient's condition, compared to only 23 percent in the placebo group. The majority of patients in the group receiving dupilumab experienced significant reductions in itch.

The study's findings set the stage for Phase III clinical trials of dupilumab, to confirm its effectiveness, monitor side effects, and compare it to commonly used treatments.

Dupilumab is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals, Inc., and Sanofi.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Guide to Brushing Your Teeth the Right Way
Resting Heart Rate
Is COVID-19 Vaccination during Pregnancy Safe?
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Allergy Drug Toxicity Types of Food Allergies Healthy Living 

Recommended Reading
Atopic Dermatitis
Atopic dermatitis is an inflammatory, non-contagious, chronic skin disorder that involves scaly and ...
Skin Disease
Skin diseases also known as dermatologic disorders are many in number and so are their causes. The ....
Allergy
An allergy is a hypersensitive disorder of immune system. Substances that often cause allergic react...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Types of Food Allergies
If you are allergic to certain food items-Watch out for what you eat...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use